Next Investors logo grey

How Creso Pharma could benefit from TGA down-scheduling of CBD


Published 15-DEC-2020 15:29 P.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma Limited (ASX: CPH; FRA: 1X8) is positioned to significantly benefit from a decision today by the Therapeutic Goods Administration (TGA) to down-schedule low dose cannabidiol (CBD) preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine).

The landmark decision will allow low-dose CBD containing products, up to a maximum of 150 mg/day, up from 6omg a day, for use in adults that have been approved by the TGA, to be supplied over-the-counter by a pharmacist, without a prescription.


The decision also outlines additional limits on dosage form and packaging requirements, including pack size and child-resistant closures.

With regards to the TGA decision, it limits over-the-counter supply to only those products that are approved by the TGA and included on the Australian Register of Therapeutic Goods (ARTG).

The decision has been welcomed by the broader community, with Medical director and addiction specialist at CA Clinics Dr Mark Hardy saying, “This could potentially result in more Australians benefiting from the therapeutic properties of cannabis. However, the effects of low-dose CBD may be negligible for many chronically ill patients.

“Pharmacists would also still need to consult with consumers to ensure they’re aware of potential drug-drug interactions, as CBD can affect the way certain other medications are metabolised. Bottom line, consumers should consult their GP before taking over-the-counter products.”

Applications can now be lodged to the TGA by sponsoring companies for inclusion of Schedule 3 CBD preparations on the ARTG.

For Creso there is only upside.

Creso Pharma has an existing portfolio of CBD products that are currently available in Australia by prescription, including cannaQIX® 50 which is sold under the ‘LozaCan’ brand. Creso will immediately explore the requirements to sell this product, as well as the company’s other GMP-manufactured ranges, more broadly to Australian consumers.

The TGA decision will also allow Creso Pharma to expedite its Heads of Agreement (HOA) with leading natural, sustainable health and lifestyle brand supplier Martin & Pleasance Pty Ltd (M&P) ( to bring Creso Pharma’s suite of cannabis-based products to the Australian market, as announced in December.

Martin & Pleasance has established reputation in natural medicines

Martin & Pleasance was established over 150 years ago and provides an extensive range of natural remedies and medicines to consumers.

The group is 100% Australian owned and operated and focuses on pioneering new and emerging products.

M&P’s leading brands include Harmony women’s health range, Ki-Immune range, Vital Nutritional Products, Schuessler Tissue Salts, Zen Joint & Pain relief, He Men’s health, as well as a comprehensive range of brands targeting consumers through various lifestyle stages and health conditions.

M&P has an extensive field force directly servicing over 4,000 pharmacies across Australia and New Zealand in addition to its online channels, grocery and practitioner suppliers.

The company also has direct interests in Canada and the UK, servicing key customers in the natural and mass channels with their brands.

Creso products to be sold under M&P brand in Australia and New Zealand

Under the non-binding agreement, the parties have confirmed their intention to negotiate and enter into a formal binding and exclusive Collaborative Agreement on or before 30 April 2021 under which it is envisaged that Creso Pharma will manufacture a range of cannabidiol products in Switzerland, which would be then sold under new and existing Martin & Pleasance brands in Australia and New Zealand.

Products expected to be sold include the company’s proprietary nutraceutical range in lozenge and tea form, which are all manufactured in a GMP-certified compliant facility.

In commenting on the significance of these regulatory changes and in particular the potential to add value for its shareholders, non-executive chairman, Adam Blumenthal said, “Today’s decision by the TGA is a major step forward for the Australian market, which we expect to grow rapidly in the near term.

"Australia has always been of considerable focus for Creso Pharma, and the company has been actively establishing its footprint through existing relationships in the country that it can leverage immediately.

"An example of this is our agreement with Martin & Pleasance, which we will now progress as quickly as possible to unlock value for our shareholders.

"We look forward to providing ongoing updates on our growth in Australia, as well as other key marketing initiatives, including Europe and North America in the coming weeks.”

After a flow of promising news in recent weeks, Creso Pharma’s share price closed at 30 cents last week, a long-term record and representative of a ten-fold gain in a fortnight.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.